Serum β2 microglobulin (β2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients

Keitaro Yokoyama, H. Yoshida, N. Matsuo, Y. Maruyama, Y. Kawamura, R. Yamamoto, K. Hanaoka, M. Ikeda, H. Yamamoto, M. Nakayama, Y. Kawaguchi, T. Hosoya

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Encapsulating peritoneal sclerosis (EPS) is a serious complication in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). The aim of this study was to find a predictor for EPS. Methods: Patients with EPS who were detected by a historical cohort study using clinical data of 219 CAPD patients at our hospital. We recruited 25 patients with EPS who were compared with the patients without EPS who were matched for age and dialysis period as controls. Differences between the two groups (non-EPS group and EPS group) with respect to age, gender, primary disease, dialysis period, serum urea nitrogen, serum creatinine, β2MG, CRP and PET (peritoneal equilibration test) category (determined by the peritoneal function testing) were analyzed. Results: According to multiple regression analysis, a high β 2MG level was an independent risk factor for EPS (odds ratio 1.162, 95% confidence interval 1.026 - 1.317, p = 0.018). Other clinical markers did not show positive significance. A ROC (receiver operating characteristic) curve was prepared to evaluate the suitability of β2MG measurement as a screening test. The sensitivity was 64% and the specificity was 80% when a β2MG level of 37.0 mg/dl was taken as the cut-off value. The odds ratio for occurrence of EPS was 8.8 when β2MG level was in the range of 35 -40 mg/dl, 13.5 when β2MG level was > 40 mg/dl and 1 when β2MG level was < 30 mg/dl. Conclusion: These findings suggest that β2MG is useful as a screening test for the onset of EPS, and that β2MG and accumulation of middle-molecular uremic substances may be related to the pathophysiology of EPS.

Original languageEnglish
Pages (from-to)121-126
Number of pages6
JournalClinical nephrology
Volume69
Issue number2
DOIs
Publication statusPublished - 2008 Feb

Keywords

  • Encapsulating peritoneal sclerosis
  • Peritoneal dialysis
  • β microglobulin

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Serum β<sub>2</sub> microglobulin (β<sub>2</sub>MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients'. Together they form a unique fingerprint.

  • Cite this

    Yokoyama, K., Yoshida, H., Matsuo, N., Maruyama, Y., Kawamura, Y., Yamamoto, R., Hanaoka, K., Ikeda, M., Yamamoto, H., Nakayama, M., Kawaguchi, Y., & Hosoya, T. (2008). Serum β2 microglobulin (β2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients. Clinical nephrology, 69(2), 121-126. https://doi.org/10.5414/cnp69121